Neurostimulation Device Market Size, Trends and Insights By Product (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Electric Stimulator), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034
Reports Description
Global Neurostimulation Devices Market was valued at USD 8,054.40 Million in 2025 and is expected to reach USD 22,299.61 Million by 2034, at a CAGR of 11.98% during the forecast period 2025 – 2034.
Neurostimulation devices refer to transplantable medical devices used for neuromodulation, a therapy that involves distributing electrical pulses into specific nerves or regions of the brain.
Neurostimulators, dark brain stimulants (DBS), gastric electric stimulants, spinal stimulants, trigeminal nerve stimulants, vaginal nerve stimulants, and transcutaneous electrical nerve stimulation (TENS) units are used in the treatment of various neurological diseases and disorders, including units such as Alzheimer’s, Parkinson’s, stroke, neuromuscular position, and highly active bladder syndrome.
Additionally, reimbursement policies and healthcare providers’ preferences affect the market for these devices. Aggressive processes such as DBS and surgical treatment oppose traditional processes and emerging technologies.
Neurostimulation devices develop an option for drug therapy for developing chronic pain and other neurological conditions in developing and emerging countries. Major applications include Parkinson’s disease, dystonia, epilepsy, and urinary incontinence.
Neurostimulation Devices Market Growth Factors
An increasing occurrence of respiratory, neurological, and other conditions is driving the market
Chronic back pain, epilepsy, treatment-resistant depression, and migraine are among some older conditions related to high economic burden globally. According to the Centers for Disease Control and Prevention, the North American region alone spends USD 5000 million on the treatment of chronic lower back pain.
Also, according to the Epilepsy Foundation of America and the World Health Organization (WHO), millions of people are suffering from epilepsy globally.
The increasing incidence of these conditions and increasing awareness and diagnosis rate globally is demanding treatment for a large patient pool. Thus, with the limited clinical consequences introduced by drugs and the growing preference for neuromodulation techniques, the demand for global neuromodulation equipment is increasing.
The introduction of advanced neurostimulation equipment by market players, including non-invasive equipment, is anticipated to adopt these devices, which further promotes the demand for these techniques.
Growing occurrence of treatment-resistant chronic conditions
The patient suffering from chronic conditions, including chronic back pain, depression, epilepsy, and sleep apnea, is demonstrating resistance to drugs and other conditions. Resistance appears in terms of slow progression of treatment and slow progress of delayed or limited results.
This has inspired healthcare providers to focus on neurostimulation techniques for the treatment of chronic conditions, running the neuromodulation devices market trend. According to the Disease Control and Prevention Center (CDC) data, an estimated 52 million people in the US suffer from chronic pain each year, including about 18 million high-effect people.
Epilepsy, treatment-resistant depression, and other chronic conditions also put a major economic burden on countries for the treatment of patients. The limited medicinal results provided by drugs in the treatment of these conditions have transferred the preference of healthcare providers to neurostimulation techniques.
The most prominently preferred techniques include spinal stimulation, deep brain stimulation, vaginal nerve stimulation, triangular nerve stimulation, and others.
Neurostimulation Devices Market: Restraints
High operational expenses obstruct adoption due to expensive parts
The main obstacle to the widespread use of neurostimulation devices is their high operating costs, which limit their access and uplift. For example, the development of spinal stimuli used to treat chronic pain is expensive because they require precise parts such as electrodes and pulse generators.
The need for healthcare providers to get specific training to transplant and manage these devices increases the burden of full value. In addition, many patients, especially those without complete insurance, may incur the cost of these treatments.
This is due to frequent maintenance, continuous monitoring of the patient, and the need for periodic upgradation. Due to this restricted access, neurostimulation therapy cannot be included more widely in standard pain care.
Neurostimulation Devices Market Trends
Growing number of clinical applications to promote market demand
Spinal stimulation is one of the most preferred techniques in treating chronic back pain, mainly due to the physical and functional abilities of the nerves in the spinal cord. Vagus nerve stimulation is mainly associated with the treatment of neurological conditions, including epilepsy.
However, despite the presence of a well-established treatment algorithm for these devices, various universities are conducting clinical tests to establish the efficacy of these devices for the treatment of other conditions. For example, the Hushan Hospital in Shanghai, China, is testing the installation of the treatment of consciousness disorders using spinal stimulation.
In addition, the USFDA inspired an upper airway stimulation device by Inspire Medical Systems Inc., an upper airway stimulation device for the treatment of sleep apnea. The device aims to treat sleep apnea in patients who are CPAP resistant.
One of the major factors inducing the market development of neuromodulation equipment is the continuous focus of the market players on R&D to establish clinical effectiveness and expand clinical applications of these devices. This, combined with the increasing preference of healthcare providers for these devices, is anticipated to increase market growth during the forecast period.
Neurostimulation Devices Market Challenge
Insufficient diagnosis and treatment rate in developing countries to prevent market growth
The prevalence of neurological conditions, including epilepsy, depression, and others, is quite high in emerging countries such as China, Brazil, and India. However, despite being significantly more prevalent, low diagnosis rates in emerging countries limit the number of patients requiring treatment.
Various factors are responsible for low diagnosis rates in these countries, including a lack of awareness among the general population and limited access to clinical facilities due to insufficient healthcare infrastructure.
This deteriorates the proportion of the diagnosis population passing through treatment due to various factors. These are some of the major factors that limit the number of patients undergoing treatment, preventing the increase in the market for neurostimulation devices.
Neurostimulation Devices Market Segmentation Analysis
Based on the application, the market is segmented into pain management, epilepsy, essential tremors, urinary and fecal incontinence, depression, dystonia, and others. Pain management dominated the market in 2024 and is expected to keep its dominance during the forecast period.
The installation of clinical efficiency of neurostimulation devices in the treatment of chronic back pain, with increasing proliferation of the condition, is mainly responsible for the dominance of the market in the pain management segment.
The neurological disorder segment is the second largest segment, which was due to more adoption of these devices for the treatment of epilepsy, depression, psychiatric disorders, and others.
The increasing prevalence of urinary incontinence and the high adoption of tri-nerve stimulants in the treatment of urinary disorders and other sections in the market are being increased. Recent approval for the treatment of respiratory disorders, including sleep apnea, is estimated to run the development of the section during the forecast period.
Based on the product type, the market is segmented into spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and gastric electric stimulators. The spinal cord stimulators dominated the market in 2024 and are expected to keep its dominance during the forecast period.
The growing prevalence of chronic back pain in developed and developing countries, as well as the increasing preference of healthcare providers for spinal stimuli on traditional drugs, is mainly increasing the growth of the section.
The increasing prevalence of neurological disorders, including depression, epilepsy, Parkinson’s disease, and others, is increasing the growth of deep brain stimulating and veg nerve stimulating segments in the global market.
The development of innovative devices and the growing prevalence of urine incontinence, supporting the development of the market, is promoting the demand for nerve stimulation.
In developed countries, the increasing number of patients undergoing noninvasive treatment for psychiatric disorders, as well as TMS techniques, is promoting the growing awareness among patients in developing countries of the development of a segment of transcranial magnetic stimuli.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 8,054.40 Million |
| Projected Market Size in 2034 | USD 22,299.61 Million |
| Market Size in 2024 | USD 7,192.71 Million |
| CAGR Growth Rate | 11.98% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Product, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your research requirements. |
Neurostimulation Devices Market Regional Analysis
By region, the neurostimulation device market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America. Among all of these, the North America region dominated the market in 2024 and is expected to keep its dominance during the forecast period.
Primary factors responsible for the region’s dominance include high diagnosis among the patient population and high adoption of neuromodulation tools for treatment rate and treatment of chronic conditions. The high proliferation of older conditions in the US and adequate reimbursement policies for these devices has further enhanced this.
Europe was the second-largest market in 2024 and is expected to keep its position during the forecast period. A well-developed healthcare infrastructure, in collaboration with non-invasive equipment in the region, is promoting the demand for these devices.
New entrants and regional players have received CE mark approval for their non-invasive devices. This is estimated to increase market growth in Europe during the forecast period. The Asia-Pacific during the forecast period is estimated to be comparatively high CAGR. Developing healthcare infrastructure, in combination with increase in per capita healthcare and improving diagnosis and treatment rates, are anticipated factors to promote market development.
Global Neurostimulation Devices Market Recent Development
- January 2024, Neurosigma, Inc. located in Los Angeles has announced that the US FDA approved its second-generation Monark ETNS system (Monark 2.0) for the treatment of pediatric ADHD. The device is approved as a monotherapy for children between 7 and 12 years of age who are not on prescription ADHD drugs.
- January 2024, the Minnesota-based Medtronic PLC announced the FDA approval of its Percept™ RC Deep Brain Stimulation (DBS) system. The rechargeable neurostimulator is the latest addition to the Perception™ family. This includes Percept™ PC neurostimulator, Brainsense™ technology, and Sensual™ directional leads.
- January 2024, Boston Scientific, headquartered in Marlboro, entered into a certain agreement to acquire Exonics, Inc. It is a medical technology company specialising in urine and bowel dysfunction equipment. The USD 3.4 Bn priced transactions, possibly the triangular neuromodulation therapy of the exon, will increase the Urology portfolio of Boston Scientific.
- May 2023, Abbott received FDA approval for its spinal stimulation (SCS) system, which had to treat chronic back pain in those who were not eligible to get surgery back or not, known as non-surgical back pain. This new signal applies to all ABS SCS products in the United States, including the ENCS platforms, and proclaims SCS families.
- In January 2023, Exonics Inc., a global medical technology company, received the approval of the US Food and Drug Administration for its fourth-generation rechargeable triangular neuromodulation system.
List of the prominent players in the Neurostimulation Devices Market:
- Medtronic
- Cyberonics
- Boston Scientific Corporation
- Jude Medical
- Nevro Corporation
- Neuronetics Inc
- NeuroPace Inc
- NeuroSigma Inc
- Cochlear Ltd
- NDI Medical
- Synapse Biomedical Inc
- MED-EL
- LivaNova PLC
- DePuy Synthes Inc
- Others
The Neurostimulation Devices Market is segmented as follows:
By Product
- Spinal Cord Stimulator
- Deep Brain Stimulator
- Sacral Nerve Stimulator
- Vagus Nerve Stimulator
- Gastric Electric Stimulator
By Application
- Pain Management
- Epilepsy
- Essential Tremor
- Urinary and Fecal Incontinence
- Depression
- Dystonia
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Neurostimulation Devices Market (2025 – 2034) (USD Million)
- 2.2 Global Neurostimulation Devices Market: snapshot
- Chapter 3. Global Neurostimulation Devices Market – Industry Analysis
- 3.1 Neurostimulation Devices Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 An increasing occurrence of respiratory and neurological
- 3.2.2 Growing occurrence of treatment-resistant chronic conditions
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- Chapter 4. Global Neurostimulation Devices Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Neurostimulation Devices Market: Company Market Share, 2024
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Neurostimulation Devices Market – Product Analysis
- 5.1 Global Neurostimulation Devices Market Overview: By Product
- 5.1.1 Global Neurostimulation Devices Market Share, By Product, 2024 and 2034
- 5.2 Spinal Cord Stimulator
- 5.2.1 Global Neurostimulation Devices Market by Spinal Cord Stimulator, 2025 – 2034 (USD Million)
- 5.3 Deep Brain Stimulator
- 5.3.1 Global Neurostimulation Devices Market by Deep Brain Stimulator, 2025 – 2034 (USD Million)
- 5.4 Sacral Nerve Stimulator
- 5.4.1 Global Neurostimulation Devices Market by Sacral Nerve Stimulator, 2025 – 2034 (USD Million)
- 5.5 Vagus Nerve Stimulator
- 5.5.1 Global Neurostimulation Devices Market by Vagus Nerve Stimulator, 2025 – 2034 (USD Million)
- 5.6 Gastric Electric Stimulator
- 5.6.1 Global Neurostimulation Devices Market by Gastric Electric Stimulator, 2025 – 2034 (USD Million)
- 5.1 Global Neurostimulation Devices Market Overview: By Product
- Chapter 6. Global Neurostimulation Devices Market – Application Analysis
- 6.1 Global Neurostimulation Devices Market Overview: By Application
- 6.1.1 Global Neurostimulation Devices Market Share, By Application, 2024 and 2034
- 6.2 Pain Management
- 6.2.1 Global Neurostimulation Devices Market by Pain Management, 2025 – 2034 (USD Million)
- 6.3 Epilepsy
- 6.3.1 Global Neurostimulation Devices Market by Epilepsy, 2025 – 2034 (USD Million)
- 6.4 Essential Tremor
- 6.4.1 Global Neurostimulation Devices Market by Essential Tremor, 2025 – 2034 (USD Million)
- 6.5 Urinary and Fecal Incontinence
- 6.5.1 Global Neurostimulation Devices Market by Urinary and Fecal Incontinence, 2025 – 2034 (USD Million)
- 6.6 Depression
- 6.6.1 Global Neurostimulation Devices Market by Depression, 2025 – 2034 (USD Million)
- 6.7 Dystonia
- 6.7.1 Global Neurostimulation Devices Market by Dystonia, 2025 – 2034 (USD Million)
- 6.8 Others
- 6.8.1 Global Neurostimulation Devices Market by Others, 2025 – 2034 (USD Million)
- 6.1 Global Neurostimulation Devices Market Overview: By Application
- Chapter 7. Neurostimulation Devices Market – Regional Analysis
- 7.1 Global Neurostimulation Devices Market Regional Overview
- 7.2 Global Neurostimulation Devices Market Share, by Region, 2024 & 2034 (USD Million)
- 7.3. North America
- 7.3.1 North America Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.3.1.1 North America Neurostimulation Devices Market, by Country, 2025 – 2034 (USD Million)
- 7.3.1 North America Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.4 North America Neurostimulation Devices Market, by Product, 2025 – 2034
- 7.4.1 North America Neurostimulation Devices Market, by Product, 2025 – 2034 (USD Million)
- 7.5 North America Neurostimulation Devices Market, by Application, 2025 – 2034
- 7.5.1 North America Neurostimulation Devices Market, by Application, 2025 – 2034 (USD Million)
- 7.6. Europe
- 7.6.1 Europe Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.6.1.1 Europe Neurostimulation Devices Market, by Country, 2025 – 2034 (USD Million)
- 7.6.1 Europe Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.7 Europe Neurostimulation Devices Market, by Product, 2025 – 2034
- 7.7.1 Europe Neurostimulation Devices Market, by Product, 2025 – 2034 (USD Million)
- 7.8 Europe Neurostimulation Devices Market, by Application, 2025 – 2034
- 7.8.1 Europe Neurostimulation Devices Market, by Application, 2025 – 2034 (USD Million)
- 7.9. Asia Pacific
- 7.9.1 Asia Pacific Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.9.1.1 Asia Pacific Neurostimulation Devices Market, by Country, 2025 – 2034 (USD Million)
- 7.9.1 Asia Pacific Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.10 Asia Pacific Neurostimulation Devices Market, by Product, 2025 – 2034
- 7.10.1 Asia Pacific Neurostimulation Devices Market, by Product, 2025 – 2034 (USD Million)
- 7.11 Asia Pacific Neurostimulation Devices Market, by Application, 2025 – 2034
- 7.11.1 Asia Pacific Neurostimulation Devices Market, by Application, 2025 – 2034 (USD Million)
- 7.12. Latin America
- 7.12.1 Latin America Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.12.1.1 Latin America Neurostimulation Devices Market, by Country, 2025 – 2034 (USD Million)
- 7.12.1 Latin America Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.13 Latin America Neurostimulation Devices Market, by Product, 2025 – 2034
- 7.13.1 Latin America Neurostimulation Devices Market, by Product, 2025 – 2034 (USD Million)
- 7.14 Latin America Neurostimulation Devices Market, by Application, 2025 – 2034
- 7.14.1 Latin America Neurostimulation Devices Market, by Application, 2025 – 2034 (USD Million)
- 7.15. The Middle-East and Africa
- 7.15.1 The Middle-East and Africa Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.15.1.1 The Middle-East and Africa Neurostimulation Devices Market, by Country, 2025 – 2034 (USD Million)
- 7.15.1 The Middle-East and Africa Neurostimulation Devices Market, 2025 – 2034 (USD Million)
- 7.16 The Middle-East and Africa Neurostimulation Devices Market, by Product, 2025 – 2034
- 7.16.1 The Middle-East and Africa Neurostimulation Devices Market, by Product, 2025 – 2034 (USD Million)
- 7.17 The Middle-East and Africa Neurostimulation Devices Market, by Application, 2025 – 2034
- 7.17.1 The Middle-East and Africa Neurostimulation Devices Market, by Application, 2025 – 2034 (USD Million)
- Chapter 8. Company Profiles
- 8.1 Medtronic
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 Cyberonics
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Boston Scientific Corporation
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 St. Jude Medical
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Nevro Corporation
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Neuronetics Inc
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 NeuroPace Inc
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 NeuroSigma Inc
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 Cochlear Ltd
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 NDI Medical
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.11 Synapse Biomedical Inc
- 8.11.1 Overview
- 8.11.2 Financials
- 8.11.3 Product Portfolio
- 8.11.4 Business Strategy
- 8.11.5 Recent Developments
- 8.12 MED-EL
- 8.12.1 Overview
- 8.12.2 Financials
- 8.12.3 Product Portfolio
- 8.12.4 Business Strategy
- 8.12.5 Recent Developments
- 8.13 LivaNova PLC
- 8.13.1 Overview
- 8.13.2 Financials
- 8.13.3 Product Portfolio
- 8.13.4 Business Strategy
- 8.13.5 Recent Developments
- 8.14 DePuy Synthes Inc
- 8.14.1 Overview
- 8.14.2 Financials
- 8.14.3 Product Portfolio
- 8.14.4 Business Strategy
- 8.14.5 Recent Developments
- 8.15 Others.
- 8.15.1 Overview
- 8.15.2 Financials
- 8.15.3 Product Portfolio
- 8.15.4 Business Strategy
- 8.15.5 Recent Developments
- 8.1 Medtronic
List Of Figures
Figures No 1 to 26
List Of Tables
Tables No 1 to 52
Prominent Player
- Medtronic
- Cyberonics
- Boston Scientific Corporation
- Jude Medical
- Nevro Corporation
- Neuronetics Inc
- NeuroPace Inc
- NeuroSigma Inc
- Cochlear Ltd
- NDI Medical
- Synapse Biomedical Inc
- MED-EL
- LivaNova PLC
- DePuy Synthes Inc
- Others
FAQs
The key factors driving the Market are An increasing occurrence of respiratory and neurological, Growing occurrence of treatment-resistant chronic conditions.
The “Pain Management” had the largest share in the global market for Neurostimulation Device.
The “Spinal Cord Stimulator” category dominated the market in 2024.
The key players in the market are Medtronic, Cyberonics, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, Neuronetics Inc, NeuroPace Inc, NeuroSigma Inc, Cochlear Ltd, NDI Medical, Synapse Biomedical Inc, MED-EL, LivaNova PLC, DePuy Synthes Inc, Others.
“North America” had the largest share in the Neurostimulation Device Market.
The global market is projected to grow at a CAGR of 11.98% during the forecast period, 2025-2034.
The Neurostimulation Device Market size was valued at USD 8,054.40 Million in 2025.